Garnet E. Peck, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Garnet E. Peck, PhD


Garnet E. Peck, PhD
Professor Emeritus of
Industrial Pharmacy
Purdue University

Garnet E. Peck is a professor emeritus and visiting professor in the department of industrial and physical pharmacy at Purdue University’s School of Pharmacy and Pharmaceutical Sciences. He received his BS (1957) in pharmacy from Ohio Northern University and MS (1959) and PhD (1962) degrees in industrial pharmacy from Purdue University. From 1962 to 1967, Peck was employed by the Mead Johnson Research Center and in 1967 he returned to Purdue University to join the department of industrial and physical pharmacy.  He was associate department head from 1989 to 1996.

Peck’s research interests include optimization of drug product design and process design, in particular those systems involving tablets, topical drug ad­sorption, flow of solid systems, dispersed systems design and evaluation, new tablet coating materials and procedures, and excipient-drug interaction. His research has resulted in more than 110 scientific publications.

Peck is a member of the APhA, the PT Section of the American Association of Pharmaceutical Scientists (AAPS), ACS, AACP, New York Academy of Science, Sigma Xi, Rho Chi, Phi Lambda Upsilon, Phi Kappa Phi and is a fellow of the AAAS, APRS, AAPS, and the American Institute of Chemists.  Peck was chairman of the IPT Section of the Academy of Pharmaceutical Sciences for 1983-84.  He was elected to the 1985-1990 United States Pharmacopeia Committee of Revision and then re-elected to the committee for 1990-1995 and 1995-2000. He was elected to the Committee of Experts, Excipients for 2000-2005. Peck is a founding member of The Catholic Academy of Science in the United States founded in 1987.

In March 1994, he was awarded by the American Pharmaceutical Association the Sidney L. Riegelman Research Achievement Award in Pharmaceutics, and he received the Pharmaceutical Technology Publishers’ Award in September 1994.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here